Monthly
US$200
Billed every month
Sign in to subscribeAs of 13 November 2026, for Norepinephrine Bitartrate Injection, 9 applications are listed as under review at China's CDE; 2 companies have filed new generic applications in 2026; the chemical-drug catalogue lists 34 holders.
Companies, stages and changes, with each record available on this page.
Listed in the US FDA Orange Book as LEVOPHED (NDA 007513, HOSPIRA INC).
Last 90 days: Accepted: 1 application
Current coverage may be incomplete
The brand names come from the US FDA Orange Book and describe US listing records for this active ingredient. They do not indicate that products under these brand names are approved or sold in China, or that Chinese applicants are affiliated with US holders.
Orange Book source export date: 2026/11/06. Version: 2026-11-06.
Showing 3 of 3 distinct brand names.
A brand with different source forms or statuses can appear on multiple rows and in both groups. Distinct brand names are counted once globally, with a limit of five.
Verified official English dosage form: Injection. Listings are grouped by the source dosage form and route; records without a clear correspondence are listed in the other group. Grouping does not establish product equivalence.
| Brand name | Applicant (source text) | Application number | Dosage form (source text) | Route (source text) | Marketing status (source text) | Approval date |
|---|---|---|---|---|---|---|
| LEVOPHED | HOSPIRA INC | NDA 007513 · Product no. 001 | INJECTABLE | INJECTION | HUMAN PRESCRIPTION DRUG | Approved prior to 1982 (exact date not listed) |
| Brand name | Applicant (source text) | Application number | Dosage form (source text) | Route (source text) | Marketing status (source text) | Approval date |
|---|---|---|---|---|---|---|
| NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | BAXTER HEALTHCARE CORP | NDA 214313 · Product no. 001, 002 | SOLUTION | INTRAVENOUS | HUMAN PRESCRIPTION DRUG | 2021/01/15 |
| NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE | INFORLIFE SA | NDA 215700 · Product no. 001, 002, 003 | SOLUTION | INTRAVENOUS | HUMAN PRESCRIPTION DRUG | 2022/09/15 |
| NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE | LONG GROVE PHARMACEUTICALS LLC | NDA 214628 · Product no. 001, 002, 003 | SOLUTION | INTRAVENOUS | HUMAN PRESCRIPTION DRUG | 2022/10/06 |
| NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | BAXTER HEALTHCARE CORP | NDA 214313 · Product no. 003 | SOLUTION | INTRAVENOUS | HUMAN PRESCRIPTION DRUG | 2023/11/21 |
| NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE | INFORLIFE SA | NDA 215700 · Product no. 004 | SOLUTION | INTRAVENOUS | HUMAN PRESCRIPTION DRUG | 2025/10/15 |
| NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE | BAXTER HEALTHCARE CORP | NDA 214313 · Product no. 004, 005, 006 | SOLUTION | INTRAVENOUS | HUMAN PRESCRIPTION DRUG | 2026/02/06 |
Same-form/route listings come first, followed by other forms/routes. Within each group, source prescription/OTC listings precede discontinued listings; unknown statuses are last. Each status bucket is ordered by earliest approval date, ascending: pre-1982 records first, missing dates last; ties by brand name, application number and product number. The first five distinct brands in this order are selected globally. All retained source facts for those brands are shown in their own groups; a brand spanning both groups counts once.
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.
Loaded records: 34 holders; 5 in the quality-and-efficacy consistency-evaluation category, and 26 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Jiangsu Run Heng Pharmaceutical Co., Ltd. romanized | Jiangsu Run Heng Pharmaceutical Co., Ltd. romanized | 国药准字H20266050 | 2026/09/22 | 1ml:2mg | Generic approved under the new chemical-drug registration classification | CDE |
| Jiangsu Run Heng Pharmaceutical Co., Ltd. romanized | Jiangsu Run Heng Pharmaceutical Co., Ltd. romanized | 国药准字H20266051 | 2026/09/22 | 4ml:8mg | Generic approved under the new chemical-drug registration classification | CDE |
| Yunnan Long Hai Tian Ran Zhi Wu Pharma Co., Ltd. romanized | Yunnan Long Hai Tian Ran Zhi Wu Pharma Co., Ltd. romanized | 国药准字H20265991 | 2026/09/15 | 4ml:8mg | Generic approved under the new chemical-drug registration classification | CDE |
| Shanxi Zhen Dong Tai Sheng Pharmaceutical Co., Ltd. romanized | Shanxi Zhen Dong Tai Sheng Pharmaceutical Co., Ltd. romanized | 国药准字H20265662 | 2026/08/18 | 4ml:8mg | Generic approved under the new chemical-drug registration classification | CDE |
| Guangzhou Bai Yun Shan Ming Xing Pharmaceutical Co., Ltd. romanized | Guangzhou Bai Yun Shan Ming Xing Pharmaceutical Co., Ltd. romanized | 国药准字H44022396 | 2026/08/17 | 1ml:2mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Zhejiang Shang Ke Biopharmaceuticals Co., Ltd. romanized | Zhejiang Shang Ke Biopharmaceuticals Co., Ltd. romanized | 国药准字H20265272 | 2026/07/21 | 4ml:8mg | Generic approved under the new chemical-drug registration classification | CDE |
| Jiangxi Ren Ke Pharmaceuticals Technology Co., Ltd. romanized | Jin Yao He Ping (Tianjin) Pharmaceutical Co., Ltd. romanized | 国药准字H20264332 | 2026/05/12 | 4ml:8mg | Generic approved under the new chemical-drug registration classification | CDE |
| Jiangxi Ren Ke Pharmaceuticals Technology Co., Ltd. romanized | Jin Yao He Ping (Tianjin) Pharmaceutical Co., Ltd. romanized | 国药准字H20264331 | 2026/05/12 | 1ml:2mg | Generic approved under the new chemical-drug registration classification | CDE |
| Yunnan Yao Ke Yuan Biopharmaceuticals Co., Ltd. romanized | Chu Xiong He Chuang Pharma Co., Ltd. romanized | 国药准字H20263643 | 2026/03/17 | 4ml:8mg | Generic approved under the new chemical-drug registration classification | CDE |
| Zhejiang Bo Xiao Biopharmaceutical Co., Ltd. romanized | Zhejiang Bo Xiao Biopharmaceutical Co., Ltd. romanized | 国药准字H20263078 | 2026/01/14 | 4ml:8mg | Generic approved under the new chemical-drug registration classification | CDE |
| Jin Zhou Ao Hong Pharma Co., Ltd. romanized | Jin Zhou Ao Hong Pharma Co., Ltd. romanized | 国药准字H20263119 | 2026/01/14 | 4ml:8mg | Generic approved under the new chemical-drug registration classification | CDE |
| HUNAN WARRANT PHARMACEUTICAL CO.,LTD | HUNAN WARRANT PHARMACEUTICAL CO.,LTD | 国药准字H20256386 | 2025/12/22 | 4ml:8mg | Generic approved under the new chemical-drug registration classification | CDE |
| Hainan Ai Ke Pharmaceutical Co., Ltd. romanized | Hainan Ai Ke Pharmaceutical Co., Ltd. romanized | 国药准字H20256126 | 2025/12/03 | 1ml:2mg | Not stated by source | CDE |
| Jiangxi Tai Ji Li Biopharmaceuticals Technology Co., Ltd. romanized | Jiangxi Yin Tao Pharma Co., Ltd. romanized | 国药准字H20256132 | 2025/12/03 | 4ml:8mg | Not stated by source | CDE |
| Sui Cheng Pharma Co., Ltd. romanized | Sui Cheng Pharma Co., Ltd. romanized | 国药准字H20256104 | 2025/12/03 | 4ml:8mg | Not stated by source | CDE |
| Xian Li Jun Pharmaceutical Co., Ltd. romanized | Xian Li Jun Pharmaceutical Co., Ltd. romanized | 国药准字H61021666 | 2025/10/31 | 1ml:2mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Zhongshan Wanhan Pharmaceuticals Co., Ltd. | Zhongshan Wanhan Pharmaceuticals Co., Ltd. | 国药准字H20255319 | 2025/09/02 | 4ml: 8mg | Generic approved under the new chemical-drug registration classification | CDE |
| Yi Chang Ren Fu Pharma Co., Ltd. romanized | Yi Chang Ren Fu Pharma Co., Ltd. romanized | 国药准字H20255191 | 2025/08/26 | 4ml:8mg | Generic approved under the new chemical-drug registration classification | CDE |
| Jia Shi (Hunan) Pharmaceuticals Technology Co., Ltd. romanized | Hunan Wu Zhou Tong Pharma Co., Ltd. romanized | 国药准字H20255142 | 2025/08/19 | 4ml:8mg | Generic approved under the new chemical-drug registration classification | CDE |
| Jia Shi (Hunan) Pharmaceuticals Technology Co., Ltd. romanized | Hunan Wu Zhou Tong Pharma Co., Ltd. romanized | 国药准字H20255141 | 2025/08/19 | 1ml:2mg | Generic approved under the new chemical-drug registration classification | CDE |
| Jiangsu Jiang Feng Pharmaceuticals Technology Co., Ltd. romanized | Jiangsu Wu Zhong Pharmaceuticals Group Co., Ltd. Suzhou Pharmaceutical Factory romanized | 国药准字H20254192 | 2025/05/20 | 4ml:8mg | Generic approved under the new chemical-drug registration classification | CDE |
| Shanghai He Feng Pharmaceutical Co., Ltd. romanized | Shanghai He Feng Pharmaceutical Co., Ltd. romanized | 国药准字H31021177 | 2025/05/14 | 1ml:2mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Zhong Run Pharma Co., Ltd. romanized | Chengdu Shi Hai Tong Pharma Co., Ltd. romanized | 国药准字H20254158 | 2025/05/13 | 1ml:2mg | Generic approved under the new chemical-drug registration classification | CDE |
| Zhong Run Pharma Co., Ltd. romanized | Chengdu Shi Hai Tong Pharma Co., Ltd. romanized | 国药准字H20254159 | 2025/05/13 | 4ml:8mg | Generic approved under the new chemical-drug registration classification | CDE |
| Jiangsu Lianhuan Pharmaceutical Co.,Ltd. | Jiangsu Lianhuan Pharmaceutical Co.,Ltd. | 国药准字H20254039 | 2025/04/30 | 4ml:8mg | Generic approved under the new chemical-drug registration classification | CDE |
| Guangzhou Rui Er Pharmaceuticals Technology Co., Ltd. romanized | Chengdu Shi Hai Tong Pharma Co., Ltd. romanized | 国药准字H20258042 | 2025/03/25 | 1ml:2mg | Generic approved under the new chemical-drug registration classification | CDE |
| Wuhan Jiu An Pharma Co., Ltd. romanized | Lang Tian Pharma (Hubei) Co., Ltd. romanized | 国药准字H20249676 | 2024/12/01 | 4ml:8mg | Generic approved under the new chemical-drug registration classification | CDE |
| Hefei Guo Yao Nuo He Pharma Co., Ltd. romanized | Guo Yao Group Guo Rui Pharma Co., Ltd. romanized | 国药准字H20249337 | 2024/11/15 | 1ml:2mg | Generic approved under the new chemical-drug registration classification | CDE |
| Hefei Guo Yao Nuo He Pharma Co., Ltd. romanized | Guo Yao Group Guo Rui Pharma Co., Ltd. romanized | 国药准字H20249338 | 2024/11/15 | 4ml:8mg | Generic approved under the new chemical-drug registration classification | CDE |
| Topfond Pharmaceutical Co., Ltd. | Topfond Pharmaceutical Co., Ltd. | 国药准字H20249334 | 2024/11/15 | 4ml∶8mg | Generic approved under the new chemical-drug registration classification | CDE |
| Fu An Pharma Group Qing Yu Tang Pharmaceutical Co., Ltd. romanized | Fu An Pharma Group Qing Yu Tang Pharmaceutical Co., Ltd. romanized | 国药准字H20244996 | 2024/09/26 | 1ml:2mg | Generic approved under the new chemical-drug registration classification | CDE |
| Guangzhou Rui Er Pharmaceuticals Technology Co., Ltd. romanized | Chengdu Shi Hai Tong Pharma Co., Ltd. romanized | 国药准字H20244852 | 2024/09/10 | 4ml:8mg | Generic approved under the new chemical-drug registration classification | CDE |
| Shijiazhuang No.4 Pharmaceutical Co., Ltd. | Shijiazhuang No.4 Pharmaceutical Co., Ltd. | 国药准字H20244708 | 2024/08/20 | See source | Generic approved under the new chemical-drug registration classification | CDE |
| Hainan Brilliant Pharmaceutical Co., Ltd. | Hainan Brilliant Pharmaceutical Co., Ltd. | 国药准字H20244336 | 2024/06/28 | 4ml:8mg | Generic approved under the new chemical-drug registration classification | CDE |
| Hainan Brilliant Pharmaceutical Co., Ltd. | Hainan Brilliant Pharmaceutical Co., Ltd. | 国药准字H20244335 | 2024/06/28 | 1ml:2mg | Generic approved under the new chemical-drug registration classification | CDE |
| Chengdu Giantech Hi-technology Development Co., Ltd. | Sichuan Mei Da Kang Jia Le Pharma Co., Ltd. romanized | 国药准字H20243327 | 2024/03/12 | 4ml:8mg | Generic approved under the new chemical-drug registration classification | CDE |
| Chengdu Giantech Hi-technology Development Co., Ltd. | Sichuan Mei Da Kang Jia Le Pharma Co., Ltd. romanized | 国药准字H20243326 | 2024/03/12 | 1ml:2mg | Generic approved under the new chemical-drug registration classification | CDE |
| Shanghai Bao Long Bio Technology Co., Ltd. romanized | Ya Bang Pharmaceuticals Co., Ltd. romanized | 国药准字H20234738 | 2023/12/29 | 4ml:8mg | Generic approved under the new chemical-drug registration classification | CDE |
| Chengdu Shuo De Pharma Co., Ltd. romanized | Chengdu Shuo De Pharma Co., Ltd. romanized | 国药准字H20234333 | 2023/10/18 | 4ml:8mg | Generic approved under the new chemical-drug registration classification | CDE |
| Hefei Yi Fan Biopharmaceutical Co., Ltd. romanized | Hefei Yi Fan Biopharmaceutical Co., Ltd. romanized | 国药准字H20233307 | 2023/03/21 | 4ml:8mg | Generic approved under the new chemical-drug registration classification | CDE |
| Tianjin Jin Yao Pharma Co., Ltd. romanized | Tianjin Jin Yao Pharma Co., Ltd. romanized | 国药准字H12020621 | 2021/10/22 | 1ml:2mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Yuan Da Pharmaceuticals (Zhongguo) Co., Ltd. romanized | Yuan Da Pharmaceuticals (Zhongguo) Co., Ltd. romanized | 国药准字H20217065 | 2021/07/30 | 4ml:8mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Yuan Da Pharmaceuticals (Zhongguo) Co., Ltd. romanized | Yuan Da Pharmaceuticals (Zhongguo) Co., Ltd. romanized | 国药准字H42021301 | 2021/07/30 | 1ml:2mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Shanghai He Feng Pharmaceutical Co., Ltd. romanized | Shanghai He Feng Pharmaceutical Co., Ltd. romanized | 国药准字H20247024 | 2024/02/05 | 4ml:8mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
Loaded records: 42 distinct approval numbers and 30 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| Guangzhou Bai Yun Shan Ming Xing Pharmaceutical Co., Ltd. romanized | 国药准字H44022396 | 1ml:2mg | Category A | XC01CAQ120B002010100375 | NHSA |
| Shanghai He Feng Pharmaceutical Co., Ltd. romanized | 国药准字H31021177 | 1ml:2mg | Category A | XC01CAQ120B002010100673 | NHSA |
| Jin Yao He Ping (Tianjin) Pharmaceutical Co., Ltd. romanized | 国药准字H12020621 | 1ml∶2mg | Category A | XC01CAQ120B002010100874 | NHSA |
| Jin Zhou Ao Hong Pharma Co., Ltd. romanized | 国药准字H20263119 | 4ml:8mg | Category A | XC01CAQ120B002010101190 | NHSA |
| Jiangsu Lianhuan Pharmaceutical Co.,Ltd. | 国药准字H20254039 | 4ml:8mg | Category A | XC01CAQ120B002010101467 | NHSA |
| Fu An Pharma Group Qing Yu Tang Pharmaceutical Co., Ltd. romanized | 国药准字H20244996 | 1ml∶2mg | Category A | XC01CAQ120B002010101877 | NHSA |
| Wuhan Jiu An Pharma Co., Ltd. romanized | 国药准字H20249676 | 4ml:8mg | Category A | XC01CAQ120B002010101949 | NHSA |
| Yuan Da Pharmaceuticals (Zhongguo) Co., Ltd. romanized | 国药准字H42021301 | 1ml:2mg | Category A | XC01CAQ120B002010101984 | NHSA |
| Xian Li Jun Pharmaceutical Co., Ltd. romanized | 国药准字H61021666 | 1ml:2mg | Category A | XC01CAQ120B002010102503 | NHSA |
| Shijiazhuang No.4 Pharmaceutical Co., Ltd. | 国药准字H20244708 | 4ml:8mg | Category A | XC01CAQ120B002010102763 | NHSA |
| Topfond Pharmaceutical Co., Ltd. | 国药准字H20249334 | 4ml∶8mg | Category A | XC01CAQ120B002010103098 | NHSA |
| Sui Cheng Pharma Co., Ltd. romanized | 国药准字H20256104 | 4ml:8mg | Category A | XC01CAQ120B002010103204 | NHSA |
| Hainan Ai Ke Pharmaceutical Co., Ltd. romanized | 国药准字H20256126 | 1ml:2mg | Category A | XC01CAQ120B002010105759 | NHSA |
| Hainan Brilliant Pharmaceutical Co., Ltd. | 国药准字H20244335 | 1ml:2mg | Category A | XC01CAQ120B002010105791 | NHSA |
| Yunnan Long Hai Tian Ran Zhi Wu Pharma Co., Ltd. romanized | 国药准字H20265991 | 4ml:8mg | Category A | XC01CAQ120B002010106286 | NHSA |
| Zhongshan Wanhan Pharmaceuticals Co., Ltd. | 国药准字H20255319 | 4ml: 8mg | Category A | XC01CAQ120B002010109920 | NHSA |
| Hefei Yi Fan Biopharmaceutical Co., Ltd. romanized | 国药准字H20233307 | 4ml:8mg | Category A | XC01CAQ120B002010182719 | NHSA |
| Shanghai Bao Long Bio Technology Co., Ltd. romanized | 国药准字H20234738 | 4ml:8mg | Category A | XC01CAQ120B002010183069 | NHSA |
| Chengdu Giantech Hi-technology Development Co., Ltd. | 国药准字H20243326 | 1ml:2mg | Category A | XC01CAQ120B002010183325 | NHSA |
| Guangzhou Rui Er Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20244852 | 4ml:8mg | Category A | XC01CAQ120B002010183450 | NHSA |
| Hefei Guo Yao Nuo He Pharma Co., Ltd. romanized | 国药准字H20249337 | 1ml:2mg | Category A | XC01CAQ120B002010183719 | NHSA |
| Jiangsu Jiang Feng Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20254192 | 4ml:8mg | Category A | XC01CAQ120B002010183817 | NHSA |
| Chengdu Shuo De Pharma Co., Ltd. romanized | 国药准字H20234333 | 4ml:8mg | Category A | XC01CAQ120B002010183830 | NHSA |
| Jiangxi Ren Ke Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20264331 | 1ml:2mg | Category A | XC01CAQ120B002010184300 | NHSA |
| Yunnan Yao Ke Yuan Biopharmaceuticals Co., Ltd. romanized | 国药准字H20263643 | 4ml:8mg | Category A | XC01CAQ120B002010184547 | NHSA |
| Jiangxi Tai Ji Li Biopharmaceuticals Technology Co., Ltd. romanized | 国药准字H20256132 | 4ml:8mg | Category A | XC01CAQ120B002010184945 | NHSA |
| Guangzhou Hui Feng De Bio Technology Co., Ltd. romanized | 国药准字H20256284 | 4ml:8mg | Category A | XC01CAQ120B002010185110 | NHSA |
| Zhejiang Shang Ke Biopharmaceuticals Co., Ltd. romanized | 国药准字H20265272 | 4ml:8mg | Category A | XC01CAQ120B002010185772 | NHSA |
| Guangzhou Bai Yun Shan Ming Xing Pharmaceutical Co., Ltd. romanized | 国药准字H44022396 | 1ml:2mg | Category A | XC01CAQ120B002010200375 | NHSA |
| Shanghai He Feng Pharmaceutical Co., Ltd. romanized | 国药准字H31021177 | 1ml:2mg | Category A | XC01CAQ120B002010200673 | NHSA |
| Jin Yao He Ping (Tianjin) Pharmaceutical Co., Ltd. romanized | 国药准字H12020621 | 1ml∶2mg | Category A | XC01CAQ120B002010200874 | NHSA |
| Jiangsu Lianhuan Pharmaceutical Co.,Ltd. | 国药准字H20254039 | 4ml:8mg | Category A | XC01CAQ120B002010201467 | NHSA |
| Fu An Pharma Group Qing Yu Tang Pharmaceutical Co., Ltd. romanized | 国药准字H20244996 | 1ml∶2mg | Category A | XC01CAQ120B002010201877 | NHSA |
| Wuhan Jiu An Pharma Co., Ltd. romanized | 国药准字H20249676 | 4ml:8mg | Category A | XC01CAQ120B002010201949 | NHSA |
| Yuan Da Pharmaceuticals (Zhongguo) Co., Ltd. romanized | 国药准字H42021301 | 1ml:2mg | Category A | XC01CAQ120B002010201984 | NHSA |
| Shijiazhuang No.4 Pharmaceutical Co., Ltd. | 国药准字H20244708 | 4ml:8mg | Category A | XC01CAQ120B002010202763 | NHSA |
| Topfond Pharmaceutical Co., Ltd. | 国药准字H20249334 | 4ml∶8mg | Category A | XC01CAQ120B002010203098 | NHSA |
| Sui Cheng Pharma Co., Ltd. romanized | 国药准字H20256104 | 4ml:8mg | Category A | XC01CAQ120B002010203204 | NHSA |
| Hainan Brilliant Pharmaceutical Co., Ltd. | 国药准字H20244335 | 1ml:2mg | Category A | XC01CAQ120B002010205791 | NHSA |
| Yunnan Long Hai Tian Ran Zhi Wu Pharma Co., Ltd. romanized | 国药准字H20265991 | 4ml:8mg | Category A | XC01CAQ120B002010206286 | NHSA |
| Hefei Yi Fan Biopharmaceutical Co., Ltd. romanized | 国药准字H20233307 | 4ml:8mg | Category A | XC01CAQ120B002010282719 | NHSA |
| Shanghai Bao Long Bio Technology Co., Ltd. romanized | 国药准字H20234738 | 4ml:8mg | Category A | XC01CAQ120B002010283069 | NHSA |
| Chengdu Giantech Hi-technology Development Co., Ltd. | 国药准字H20243326 | 1ml:2mg | Category A | XC01CAQ120B002010283325 | NHSA |
| Guangzhou Rui Er Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20244852 | 4ml:8mg | Category A | XC01CAQ120B002010283450 | NHSA |
| Hefei Guo Yao Nuo He Pharma Co., Ltd. romanized | 国药准字H20249337 | 1ml:2mg | Category A | XC01CAQ120B002010283719 | NHSA |
| Jiangsu Jiang Feng Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20254192 | 4ml:8mg | Category A | XC01CAQ120B002010283817 | NHSA |
| Chengdu Shuo De Pharma Co., Ltd. romanized | 国药准字H20234333 | 4ml:8mg | Category A | XC01CAQ120B002010283830 | NHSA |
| Yunnan Yao Ke Yuan Biopharmaceuticals Co., Ltd. romanized | 国药准字H20263643 | 4ml:8mg | Category A | XC01CAQ120B002010284547 | NHSA |
| Guangzhou Hui Feng De Bio Technology Co., Ltd. romanized | 国药准字H20256284 | 4ml:8mg | Category A | XC01CAQ120B002010285110 | NHSA |
| Zhejiang Shang Ke Biopharmaceuticals Co., Ltd. romanized | 国药准字H20265272 | 4ml:8mg | Category A | XC01CAQ120B002010285772 | NHSA |
| Shanghai He Feng Pharmaceutical Co., Ltd. romanized | 国药准字H31021177 | 1ml:2mg | Category A | XC01CAQ120B002010300673 | NHSA |
| Jin Yao He Ping (Tianjin) Pharmaceutical Co., Ltd. romanized | 国药准字H12020621 | 1ml∶2mg | Category A | XC01CAQ120B002010300874 | NHSA |
| Fu An Pharma Group Qing Yu Tang Pharmaceutical Co., Ltd. romanized | 国药准字H20244996 | 1ml∶2mg | Category A | XC01CAQ120B002010301877 | NHSA |
| Yuan Da Pharmaceuticals (Zhongguo) Co., Ltd. romanized | 国药准字H42021301 | 1ml:2mg | Category A | XC01CAQ120B002010301984 | NHSA |
| Hainan Brilliant Pharmaceutical Co., Ltd. | 国药准字H20244335 | 1ml:2mg | Category A | XC01CAQ120B002010305791 | NHSA |
| Hefei Yi Fan Biopharmaceutical Co., Ltd. romanized | 国药准字H20233307 | 4ml:8mg | Category A | XC01CAQ120B002010382719 | NHSA |
| Shanghai Bao Long Bio Technology Co., Ltd. romanized | 国药准字H20234738 | 4ml:8mg | Category A | XC01CAQ120B002010383069 | NHSA |
| Guangzhou Rui Er Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20244852 | 4ml:8mg | Category A | XC01CAQ120B002010383450 | NHSA |
| Shanghai He Feng Pharmaceutical Co., Ltd. romanized | 国药准字H31021176 | 2ml:10mg | Category A | XC01CAQ120B002020100673 | NHSA |
| Yuan Da Pharmaceuticals (Zhongguo) Co., Ltd. romanized | 国药准字H20217065 | 4ml:8mg | Category A | XC01CAQ120B002020101984 | NHSA |
| Xian Li Jun Pharmaceutical Co., Ltd. romanized | 国药准字H61021666 | 1ml:2mg | Category A | XC01CAQ120B002020102503 | NHSA |
| SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED | 国药准字H37020634 | 2ml:10mg | Category A | XC01CAQ120B002020104187 | NHSA |
| Hainan Brilliant Pharmaceutical Co., Ltd. | 国药准字H20244336 | 4ml:8mg | Category A | XC01CAQ120B002020105791 | NHSA |
| Hefei Yi Fan Biopharmaceutical Co., Ltd. romanized | 国药准字H20247146 | 1ml: 2mg | Category A | XC01CAQ120B002020182719 | NHSA |
| Shanghai Bao Long Bio Technology Co., Ltd. romanized | 国药准字H20269012 | 1ml:2mg | Category A | XC01CAQ120B002020183069 | NHSA |
| Chengdu Giantech Hi-technology Development Co., Ltd. | 国药准字H20243327 | 4ml:8mg | Category A | XC01CAQ120B002020183325 | NHSA |
| Guangzhou Rui Er Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20258042 | 1ml:2mg | Category A | XC01CAQ120B002020183450 | NHSA |
| Hefei Guo Yao Nuo He Pharma Co., Ltd. romanized | 国药准字H20249338 | 4ml:8mg | Category A | XC01CAQ120B002020183719 | NHSA |
| Jiangxi Ren Ke Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20264332 | 4ml:8mg | Category A | XC01CAQ120B002020184300 | NHSA |
| SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED | 国药准字H37020634 | 2ml:10mg | Category A | XC01CAQ120B002020204187 | NHSA |
| Hainan Brilliant Pharmaceutical Co., Ltd. | 国药准字H20244336 | 4ml:8mg | Category A | XC01CAQ120B002020205791 | NHSA |
| Shanghai Bao Long Bio Technology Co., Ltd. romanized | 国药准字H20269012 | 1ml:2mg | Category A | XC01CAQ120B002020283069 | NHSA |
| Chengdu Giantech Hi-technology Development Co., Ltd. | 国药准字H20243327 | 4ml:8mg | Category A | XC01CAQ120B002020283325 | NHSA |
| Yuan Da Pharmaceuticals (Zhongguo) Co., Ltd. romanized | 国药准字H20217065 | 4ml:8mg | Category A | XC01CAQ120B002020283383 | NHSA |
| Guangzhou Rui Er Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20258042 | 1ml:2mg | Category A | XC01CAQ120B002020283450 | NHSA |
| Hefei Guo Yao Nuo He Pharma Co., Ltd. romanized | 国药准字H20249338 | 4ml:8mg | Category A | XC01CAQ120B002020283719 | NHSA |
| Shanghai He Feng Pharmaceutical Co., Ltd. romanized | 国药准字H20247024 | 4ml:8mg | Category A | XC01CAQ120B002030100673 | NHSA |
| Yuan Da Pharmaceuticals (Zhongguo) Co., Ltd. romanized | 国药准字H42022048 | 2ml:10mg | Category A | XC01CAQ120B002030101984 | NHSA |
| Shanghai He Feng Pharmaceutical Co., Ltd. romanized | 国药准字H20247024 | 4ml:8mg | Category A | XC01CAQ120B002030200673 | NHSA |
| Yuan Da Pharmaceuticals (Zhongguo) Co., Ltd. romanized | 国药准字H42022048 | 2ml:10mg | Category A | XC01CAQ120B002030201984 | NHSA |
| Yuan Da Pharmaceuticals (Zhongguo) Co., Ltd. romanized | 国药准字H42022048 | 2ml:10mg | Category A | XC01CAQ120B002030301984 | NHSA |
| Jiangsu Run Heng Pharmaceutical Co., Ltd. romanized | 国药准字H20266050 | 1ml:2mg | Category A | XC01CAQ120B002010185560 | NHSA |
| Jiangsu Run Heng Pharmaceutical Co., Ltd. romanized | 国药准字H20266050 | 1ml:2mg | Category A | XC01CAQ120B002010285560 | NHSA |
| Jiangsu Run Heng Pharmaceutical Co., Ltd. romanized | 国药准字H20266051 | 4ml:8mg | Category A | XC01CAQ120B002020185560 | NHSA |
| Jiangsu Run Heng Pharmaceutical Co., Ltd. romanized | 国药准字H20266051 | 4ml:8mg | Category A | XC01CAQ120B002020285560 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Loaded records: 9 filings and 7 distinct first applicants.
Generic 8 · Supplement 1
Loaded records: 2 filings and 2 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Xu Bi Di Pharma (Cang Zhou) Co., Ltd. romanized | CYHS2602391 | Generic | 2026/09/23 | Not stated by source | CDE |
| Hebei Ke Yuan Pharma Co., Ltd. romanized; Hebei Ren He Yi Kang Pharma Co., Ltd. romanized | CYHS2600955 | Generic | 2026/04/24 | Not stated by source | CDE |
Non-component matches: 20 companies with A status and 4 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 重酒石酸去甲肾上腺素 · No verified English name | Shandong Chen Long Pharma Co., Ltd. romanized | Y20260000628 | I | Exact ingredient | 2026/07/23 | CDE |
| 重酒石酸去甲肾上腺素 · No verified English name | Xu Bi Di Pharma (Cang Zhou) Co., Ltd. romanized | Y20250001092 | I | Exact ingredient | 2025/10/20 | CDE |
| 重酒石酸去甲肾上腺素 · No verified English name | Zhi En Bio Technology Co., Ltd. romanized | Y20250001057 | I | Exact ingredient | 2025/10/15 | CDE |
| 重酒石酸去甲肾上腺素 · No verified English name | Shanxi Zhen Dong Tai Sheng Pharmaceutical Co., Ltd. romanized | Y20240001074 | A | Exact ingredient | 2026/07/13 | CDE |
| 重酒石酸去甲肾上腺素 · No verified English name | Zhejiang Shang Tai Biopharmaceutical Co., Ltd. romanized | Y20240000586 | A | Exact ingredient | 2026/09/19 | CDE |
| 重酒石酸去甲肾上腺素 · No verified English name | Hunan Hua Na Da Pharmaceutical Factory Shou Xing Drug Co., Ltd. romanized | Y20240000250 | A | Exact ingredient | 2025/10/22 | CDE |
| 重酒石酸去甲肾上腺素 · No verified English name | Jin Zhou Ao Hong Pharma Co., Ltd. romanized | Y20240000355 | A | Exact ingredient | 2026/11/05 | CDE |
| 重酒石酸去甲肾上腺素 · No verified English name | Zhejiang Bo Xiao Biopharmaceutical Co., Ltd. romanized | Y20240000258 | A | Exact ingredient | 2025/12/18 | CDE |
| 重酒石酸去甲肾上腺素 · No verified English name | Hebei Chuang Jian Pharma Co., Ltd. romanized | Y20230000508 | A | Exact ingredient | 2025/02/12 | CDE |
| 重酒石酸去甲肾上腺素 · No verified English name | Anhui Mei Nuo Hua Drug Chemical Co., Ltd. romanized | Y20230000869 | A | Exact ingredient | 2026/01/01 | CDE |
| 重酒石酸去甲肾上腺素 · No verified English name | Zhongshan Wanhan Pharmaceuticals Co., Ltd. | Y20230000665 | A | Exact ingredient | 2025/08/02 | CDE |
| 重酒石酸去甲肾上腺素 · No verified English name | Bo Rui Pharmaceutical (Suzhou) Co., Ltd. romanized | Y20230000409 | A | Exact ingredient | 2024/11/29 | CDE |
| 重酒石酸去甲肾上腺素 · No verified English name | Shanghai Xian Dai Ha Sen (Shang Qiu) Pharma Co., Ltd. romanized | Y20230000575 | A | Exact ingredient | 2025/02/07 | CDE |
| 重酒石酸去甲肾上腺素 · No verified English name | Hainan Zhuo Ke Pharmaceutical Co., Ltd. romanized | Y20220001319 | A | Exact ingredient | 2024/07/17 | CDE |
| 重酒石酸去甲肾上腺素 · No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20220001149 | A | Exact ingredient | 2025/05/20 | CDE |
| 重酒石酸去甲肾上腺素 · No verified English name | Hebei Guang Xiang Pharmaceutical Co., Ltd. romanized | Y20220000836 | A | Exact ingredient | 2024/04/13 | CDE |
| 重酒石酸去甲肾上腺素 · No verified English name | Chengdu Xin Heng Chuang Pharma Co., Ltd. romanized | Y20220000724 | A | Exact ingredient | 2026/01/22 | CDE |
| 重酒石酸去甲肾上腺素 · No verified English name | Shenzhen Wo Lan De Pharma Co., Ltd. romanized | Y20220000298 | I | Exact ingredient | 2023/12/26 | CDE |
| 重酒石酸去甲肾上腺素 · No verified English name | Hubei Mei Lin Pharma Co., Ltd. romanized | Y20220000243 | A | Exact ingredient | 2024/02/29 | CDE |
| 重酒石酸去甲肾上腺素 · No verified English name | Sichuan Qing Mu Pharmaceutical Co., Ltd. romanized | Y20210001069 | A | Exact ingredient | 2025/01/25 | CDE |
| 重酒石酸去甲肾上腺素 · No verified English name | Su Zhou Yi Fan Pharma Co., Ltd. romanized | Y20210000170 | A | Exact ingredient | 2024/05/21 | CDE |
| 重酒石酸去甲肾上腺素 · No verified English name | ChemPacific Corp | Y20200000850 | A | Exact ingredient | 2023/07/04 | CDE |
| 重酒石酸去甲肾上腺素 · No verified English name | Wuhan Wu Yao Pharmaceutical Co., Ltd. romanized | Y20190009540 | A | Exact ingredient | 2025/06/17 | CDE |
| 重酒石酸去甲肾上腺素 · No verified English name | Shanxi Zhen Dong Tai Sheng Pharmaceutical Co., Ltd. romanized | Y20190006135 | A | Exact ingredient | 2025/11/04 | CDE |
| 重酒石酸去甲肾上腺素 · No verified English name | Cambrex Profarmaco Milano S.r.l. | Y20180000333 | A | Exact ingredient | 2024/08/07 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/13 06:39. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.
CYHS2602391
Fact date: 2026/09/23 · Site observation date: 2026/10/22
View source ↗Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 7/30; discovered pending details: 13. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
US$200
Billed every month
Sign in to subscribeUS$540
Billed every three months
US$180 per month
Sign in to subscribeUS$1,920
Billed every year
US$160 per month
Sign in to subscribeSeparate one-time purchase
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
Billed by Creem, our merchant of record · Terms · Refund policy